title: Radiation therapy as treatment for stage T1c prostate cancers.
abstract: Preliminary outcomes are reported for 202 patients with T1c prostate cancer treated with three-dimensional conformal radiation treatment (3DCRT). At 5 years, actuarial freedom from failure is demonstrated in 97% of patients with pretreatment PSA levels of < 10 ng/ml, in 88% of those with PSA levels of 10-19.9 ng/ml, and in 91% of young patients (< or = 65 years) with PSA levels of < 20 ng/ml. The late morbidity following this technology is extremely favorable, with < 1% of patients developing serious GI sequelae, < 1% using a daily pad for incontinence, and 61% maintaining sexual potency. Continued development and use of 3DCRT technology is indicated for patients who elect external beam radiation treatment.
authors.affiliation: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
authors.forename: G E
authors.initials: GE
authors.lastname: Hanks
authors.forename: A L
authors.initials: AL
authors.lastname: Hanlon
authors.forename: W H
authors.initials: WH
authors.lastname: Pinover
authors.forename: T I
authors.initials: TI
authors.lastname: al-Saleem
authors.forename: T E
authors.initials: TE
authors.lastname: Schultheiss
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy*; D011832:Radiation Injuries; D012725:Sexual Behavior / Q000528:radiation effects; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists